Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Spillane

Showing results (201-210 of 223) with videos related to

Pageof 23
Sort By:
Nature Medicine|February 9, 2021
Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)Alexander M Menzies, Rodabe N Amaria, Elisa A Rozeman, et al.
Cancer Cell|December 24, 2021
Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordanceFelicity Newell, Ines Pires da Silva, Peter A Johansson, et al.
Cancer Cell|February 7, 2025
Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordanceFelicity Newell, Ines Pires da Silva, Peter A Johansson, et al.
The Journal of Experimental Medicine|March 15, 2023
IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanomaIrene L M Reijers, Disha Rao, Judith M Versluis, et al.
European Journal of Cancer (Oxford, England : 1990)|November 27, 2024
Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neoIrene L M Reijers, Alexander M Menzies, Marta Lopez-Yurda, et al.
Nature Medicine|September 22, 2022
Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiomeRebecca C Simpson, Erin R Shanahan, Marcel Batten, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2020
Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III MelanomaLauren E Haydu, Serigne N Lo, Jennifer L McQuade, et al.
Journal for Immunotherapy of Cancer|March 25, 2025
FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanomaLi Zhou, Milton Jose Barros E Silva, Edward Hsiao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 21, 2021
Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanomaR V Rawson, C Adhikari, C Bierman, et al.
Nature Communications|October 17, 2020
Whole-genome sequencing of acral melanoma reveals genomic complexity and diversityFelicity Newell, James S Wilmott, Peter A Johansson, et al.
Pageof 23

Showing results (201-210 of 223) with videos related to

Sort By:
Pageof 23
Nature Medicine|February 9, 2021
Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)Alexander M Menzies, Rodabe N Amaria, Elisa A Rozeman, et al.
Cancer Cell|December 24, 2021
Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordanceFelicity Newell, Ines Pires da Silva, Peter A Johansson, et al.
Cancer Cell|February 7, 2025
Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordanceFelicity Newell, Ines Pires da Silva, Peter A Johansson, et al.
The Journal of Experimental Medicine|March 15, 2023
IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanomaIrene L M Reijers, Disha Rao, Judith M Versluis, et al.
European Journal of Cancer (Oxford, England : 1990)|November 27, 2024
Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neoIrene L M Reijers, Alexander M Menzies, Marta Lopez-Yurda, et al.
Nature Medicine|September 22, 2022
Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiomeRebecca C Simpson, Erin R Shanahan, Marcel Batten, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2020
Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III MelanomaLauren E Haydu, Serigne N Lo, Jennifer L McQuade, et al.
Journal for Immunotherapy of Cancer|March 25, 2025
FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanomaLi Zhou, Milton Jose Barros E Silva, Edward Hsiao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 21, 2021
Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanomaR V Rawson, C Adhikari, C Bierman, et al.
Nature Communications|October 17, 2020
Whole-genome sequencing of acral melanoma reveals genomic complexity and diversityFelicity Newell, James S Wilmott, Peter A Johansson, et al.
Pageof 23